Research and Development Expenses Breakdown: Merck & Co., Inc. vs Catalyst Pharmaceuticals, Inc.

R&D Spending: Merck vs. Catalyst Pharmaceuticals

__timestampCatalyst Pharmaceuticals, Inc.Merck & Co., Inc.
Wednesday, January 1, 2014101177747180000000
Thursday, January 1, 2015118013426704000000
Friday, January 1, 2016113699417194000000
Sunday, January 1, 2017113752379982000000
Monday, January 1, 2018199192049752000000
Tuesday, January 1, 2019188427529872000000
Wednesday, January 1, 20201649671513397000000
Friday, January 1, 20211693600012245000000
Saturday, January 1, 20221978900013548000000
Sunday, January 1, 20239315000030531000000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. Merck, a global leader, consistently allocated substantial resources, peaking at approximately $30 billion in 2023, a 300% increase from 2014. This commitment underscores Merck's dedication to pioneering new treatments.

Conversely, Catalyst Pharmaceuticals, a smaller player, showed a more modest yet significant growth in R&D spending. From 2014 to 2023, their investment surged by over 800%, reaching nearly $93 million. This remarkable increase highlights Catalyst's strategic focus on niche markets and specialized therapies.

These trends reflect broader industry dynamics, where established giants and agile newcomers alike drive medical advancements through strategic R&D investments.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025